Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Four Deaths Prompt FDA Safety Concerns About Novel Schizophrenia Drug

(MedPage Today) -- The FDA flagged a potential safety signal after four deaths were reported among patients with treatment-resistant schizophrenia who received investigational evenamide in clinical trials, Newron Pharmaceuticals said Thursday...

Four Deaths Prompt FDA Safety Concerns About Novel Schizophrenia Drug

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Thursday 8 October →